GlassScriptPhysician profile
Hiram Lkh Young
NPI 1275572299
$8,167.10
in general payments reported to CMS, 2019-2025
25 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $929 · 2021: $1,114 · 2022: $1,361 · 2023: $1,690 · 2024: $1,615 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,620.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,951.68 | 2020-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,503.99 | 2019-2025 | Biktarvy, Epclusa, Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $770.75 | 2020-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $617.53 | 2020-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Janssen Biotech, INC. | $562.95 | 2019-2023 | Prezcobix |
| Indivior INC. | $464.98 | 2023-2024 | Perseris, Sublocade |
| Abbvie INC. | $352.08 | 2021-2025 | Vraylar, Dalvance |
| Otsuka America Pharmaceutical, INC. | $281.27 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Novartis Pharmaceuticals Corporation | $240.97 | 2019-2025 | |
| Emd Serono, INC. | $56.27 | 2024-2025 | |
| Madrigal Pharmaceuticals | $46.14 | 2025 | Rezdiffra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.65 | 2023 | |
| Janssen Pharmaceuticals, INC | $41.02 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Dexcom, INC. | $32.18 | 2022-2023 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $28.51 | 2024 | Ingrezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.36 | 2023 | Camzyos |
| Glaxosmithkline, LLC. | $21.58 | 2020 | |
| Novo Nordisk INC | $20.19 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.34 | 2023 | Prehevbrio |
| Alkermes, INC. | $16.18 | 2023 | Lybalvi |
| Organon LLC | $15.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.71 | 2020 | |
| Napo Pharmaceuticals INC | $13.36 | 2019 | |
| Allergan, INC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiram Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.